United States Patent 9,566,286: Scope, Claims, and U.S. Patent Landscape
What does US 9,566,286 claim in practice?
US 9,566,286 claims a pressurized metered spray container that stores and dispenses a substantially anhydrous topical combination of:
- Calcipotriol or calcipotriol monohydrate
- A betamethasone ester (specified as dipropionate or valerate in dependent claims)
- Dissolved in pharmaceutically acceptable propellant:
- Dimethyl ether (DME), or
- A propellant mixture of DME plus a “second propellant” from a defined class (C3-5 alkanes and halogenated lower hydrocarbons listed)
- With a lipid carrier that is solubilized or suspended in the propellant
- The container is a metal can with a chemically inert internal lining chosen from polyimide-polyamide resin, polyamide, and polyimide
- A valve assembly with an actuator that releases the composition as a spray
The claim set is built to cover both:
1) the drug formulation architecture (drug + ester + DME or DME/second-propellant + lipid carrier + substantially anhydrous), and
2) the hardware architecture (pressurized metal container lined with specific inert coatings + defined valve construction and dimensional features).
Core independent claim (Claim 1): protected invention boundary
Claim 1 requires all of the following elements simultaneously:
- Pressurized container for dispensing a topical composition onto affected skin.
- Metal container body that is:
- Sprayable and storage stable
- Stores a substantially anhydrous topical composition
- Composition content
- Calcipotriol or calcipotriol monohydrate (therapeutically effective amount)
- Betamethasone ester (therapeutically effective amount)
- Dissolved in a pharmaceutically acceptable propellant
- Either DME alone, or
- A propellant mixture with:
- First propellant: DME
- Second propellant: selected from:
- C3-5 alkanes
- hydrofluoroalkanes
- hydrochloroalkanes
- fluoroalkanes
- chlorofluoroalkanes
- Lipid carrier
- Present as a pharmaceutically acceptable lipid carrier that is solubilized or suspended in the propellant/mixture.
- Valve assembly
- Includes an actuator that releases the composition as a spray.
- Chemical inert lining
- The metal container body is lined with a coating selected from:
- polyimide-polyamide resin
- polyamide
- polyimide
This is a combined formulation + container/valve claim. Design-arounds that avoid only the formulation or only the hardware will not eliminate infringement exposure if the remaining elements still meet Claim 1.
What do the dependent claims add to the scope?
How do Claim 2-4 narrow the container structure and material?
- Claim 2: specifies the container includes:
- metal container body containing the composition
- a dip tube
- valve assembly comprising:
- valve cup
- valve body
- actuator
- Claim 3: container body metal is one of:
- stainless steel, tinplate, aluminium/aluminium alloy, or anodised aluminium
- Claim 4: narrows further to:
- aluminium or aluminium alloy
How do Claim 5-9 define the internal coating and seals?
- Claim 5: lining coating is specifically polyimide-polyamide resin.
- Claim 6: adds chemically inert gaskets/seals.
- Claim 7: seals are impermeable to the propellant/mixture.
- Claim 8: seals are selected from:
- fluoroelastomers
- FEP (fluorinated ethylene-propylene copolymer)
- FPM (fluororubber)
- EPDM (ethylene-propylene diene monomer rubber)
How do Claim 9-12 set the dip tube and valve geometry?
- Claim 9: dip tube material is:
- polyethylene or polypropylene
- Claim 10: valve assembly construction:
- valve cup crimped to container body
- valve body with valve stem and spring
- actuator depressed to expel composition
- Claim 11: valve stem includes at least one aperture diameter:
- Claim 12: actuator insert has terminal orifice diameter:
How do Claim 13-18 define the drug and propellant mixture ratios?
- Claim 13: betamethasone ester is:
- betamethasone dipropionate or betamethasone valerate
- Claim 14: second propellant is a C3-5 alkane
- Claim 15: C3-5 alkane is:
- n-propane, isopropane, n-butane, or isobutane
- Claim 16: narrows to:
- Claim 17: ratio of (n-butane or isobutane) : DME is:
- Claim 18: ratio of (n-butane and/or isobutane) : DME is:
How does Claim 19 specify the valve stem material?
- Claim 19: valve stem material is:
- polyamide or acetal (POM)
Claim chart style: element-by-element infringement mapping (Claim 1)
Use this as the practical checklist for assessing product and competitor exposure.
| Claim 1 element |
What it requires |
Your assessment lever |
| Pressurized container dispensing topical composition by spray |
Container + valve actuator produce spray |
Check propellant can/valve system |
| Metal container body stores substantially anhydrous composition |
Anhydrous storage stability |
Composition water content and formulation stability |
| Calcipotriol or calcipotriol monohydrate |
Exact actives covered by claim |
Drug identity |
| Betamethasone ester |
Ester identity covered in dependent claims |
Ester type |
| Dissolved in propellant |
Dissolution in DME or mixture |
Whether actives are in DME-based propellant |
| Propellant selection |
DME alone OR DME + defined second propellant class |
Whether mixture uses second propellant category |
| Lipid carrier solubilized or suspended |
Lipid excipient present and compatible |
Presence/type of lipid carrier |
| Metal lining: polyimide-polyamide resin OR polyamide OR polyimide |
Specific chemically inert internal coating class |
Lining/coating material selection |
| Valve assembly with actuator releasing as spray |
Valve geometry and spray mechanism |
Valve design and actuation |
What the claims do not lock down (where design-arounds can exist)
The claim language given is highly specific on core elements, but it does not define certain parameters, leaving potential freedom to design around in those dimensions without eliminating infringement risk from the remaining elements.
Key areas not explicitly constrained in the provided claim set:
- Exact lipid carrier identity (only “pharmaceutically acceptable lipid carrier”)
- Exact concentrations of each drug and lipid (only “therapeutically effective amount”)
- Specific particle size/morphology beyond “substantially anhydrous”
- Exact valve brand or specific manufacturing methods beyond crimping and geometry (dimensional features provided for apertures/orifices only in dependent claims)
In practice, infringement is still determined by whether the product includes the specific required combinations from Claim 1.
U.S. patent landscape for calcipotriol + betamethasone topical combinations (hardware-influenced)
Where this patent sits conceptually
US 9,566,286 is a device-tinged formulation claim: it locks both the drug-propellant-lipid system and the container internals (lined metal body and inert seals) into a single protected combination.
This structure is strategically positioned to capture competitors who:
- copy the formulation concept (DME-driven anhydrous calcipotriol/betamethasone ester + lipid carrier), but
- rely on standard metal can linings and seals, or
- use valve internals not materially changed from the claimed configuration.
Why the coating and seals matter in the landscape
Many topical aerosol patents focus on:
- active combinations
- propellant choice
- anhydrous stability
- solubilization vehicles
US 9,566,286 pushes into the “containment compatibility” layer:
- internal lining must be selected from polyimide-polyamide, polyamide, or polyimide
- seals are required to be chemically inert and, in dependent claims, impermeable
- seal material is constrained (fluoroelastomers, FEP, FPM, EPDM)
In competitor portfolios, this typically forces either:
- a change to liner chemistry and possibly valve elastomer compatibility, or
- adoption of a licensing position for the containment layer.
How competitor risk changes with product choices
| Competitor approach |
Claim 1 risk outcome (from the scope provided) |
| Keep calcipotriol + betamethasone ester + DME propellant system but use a different metal can liner |
High risk if still within polyimide/polyamide/polyimide-polyamide lining classes are absent only; depends if Claim 1 requires the specified liner (it does). |
| Use different propellant not in DME or DME/second-class |
Lower risk if propellant element is not met (Claim 1 requires DME or DME mixture with defined second class). |
| Use different lipid excipient type but still a “lipid carrier” |
Still at risk if it meets “lipid carrier” definition and is solubilized/suspended in propellant. |
| Keep the drug/propol / lipid system but use a non-metal or unlined container |
Avoids Claim 1 if the metal-lined-with-inert-coating requirement is not met. |
| Change valve/orifice sizes to avoid dependent Claim 11-12 |
Can reduce dependent claim exposure; does not avoid Claim 1 if actuator releases spray and other Claim 1 elements remain. |
How to read the patent family logic (based on dependent claim layering)
Without the underlying file history text here, the dependent claim construction still reveals the likely “claim strategy”:
- Start broad in Claim 1: formulation + DME/Mixture + lipid carrier + spray valve + inert lining.
- Add manufacturing realism via Claim 2, 3, 10: dip tube, valve cup crimping, valve body with stem/spring.
- Add specific dimensional constraints in dependent claims (valve apertures/orifices): narrows capture of exact component suppliers or standardized aerosol valve designs.
- Add a propellant mixture ratio window (6:1 to 0:1 v/v) for C3-5 alkane/DME: targets a particular miscibility and aerosol performance region for DME-based systems.
- Add seal and impermeability constraints: targets compatibility failures and prevents using “standard” elastomers that swell with propellants.
Key Takeaways
- US 9,566,286 (Claim 1) is a combined formulation-plus-aerosol-container claim requiring: anhydrous calcipotriol (or monohydrate) + betamethasone ester dissolved in DME or DME/defined second propellant class, plus a lipid carrier and a spray valve, inside a metal can lined with polyimide-polyamide/polyamide/polyimide.
- Dependent claims narrow hardware and propellant specifics: aluminum body, specified dip tube materials, inert impermeable seals (fluoroelastomers/FEP/FPM/EPDM), valve geometry (0.05–1 mm stem apertures; 0.3–1.5 mm actuator orifice), and C3-5 alkane/DME ratios (6:1 to 0:1 v/v).
- The patent’s strongest competitive chokepoint in the U.S. landscape is the internal coating and seal system compatibility paired with a DME-based anhydrous dual-active calcipotriol/betamethasone ester formulation.
FAQs
1) Does US 9,566,286 require calcipotriol to be present as monohydrate?
No. Claim 1 covers calcipotriol or calcipotriol monohydrate.
2) Can the formulation use DME mixtures with C3-5 alkanes and still fall within Claim 1?
Yes. Claim 1 allows DME as first propellant plus a second propellant from the defined class, including C3-5 alkanes.
3) Is the internal can lining required in Claim 1?
Yes. Claim 1 requires the metal container body to be lined with a coating selected from polyimide-polyamide resin, polyamide, or polyimide.
4) Do the valve orifice and aperture dimensions appear only in dependent claims?
Yes. The 0.05–1 mm valve stem aperture and 0.3–1.5 mm actuator insert orifice are in dependent claims (Claim 11 and Claim 12), narrowing but not replacing the Claim 1 spray actuator requirement.
5) Is the betamethasone ester limited to dipropionate or valerate?
In dependent Claim 13 yes. Claim 1 broadly requires “a betamethasone ester,” with specific examples in dependent claims.
References (APA)
[1] U.S. Patent No. 9,566,286.
